Anzeige
Mehr »
Samstag, 30.05.2026 - Börsentäglich über 12.000 News
Die nächste große Rohstoff-Sensation? Dieses Unternehmen besitzt das größte Wolfram-Portfolio der USA
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853260 | ISIN: US4781601046 | Ticker-Symbol: JNJ
Tradegate
29.05.26 | 21:39
193,40 Euro
+0,16 % +0,30
1-Jahres-Chart
JOHNSON & JOHNSON Chart 1 Jahr
5-Tage-Chart
JOHNSON & JOHNSON 5-Tage-Chart
RealtimeGeldBriefZeit
193,16193,5429.05.
192,62193,5629.05.

Aktuelle News zur JOHNSON & JOHNSON Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05:34Während Merck, Amgen, Novo Nordisk und Fresenius Milliarden bewegen, wächst die Fantasie im Zelltherapie-Sektor
04:42Johnson & Johnson Reports Promising Phase 1/1b Results In Advanced Lung Cancer298NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced updated findings from the Phase 1/1b CHRYSALIS-2 study, which evaluated intravenous RYBREVANT (amivantamab-vmjw) in combination with...
► Artikel lesen
FrJohnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade2
FrWeekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart531NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple...
► Artikel lesen
FrJohnson & Johnson Reports Positive Data For TECVAYLI As Early As First Relapse In Multiple Myeloma282NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) on Friday reported new positive results from the Phase 3 MajesTEC-9 study evaluating TECVAYLI in patients with relapsed or refractory multiple...
► Artikel lesen
Fr4 stocks to watch on Friday: JNJ, UNH, COST, and ADSK19
JOHNSON & JOHNSON Aktie jetzt für 0€ handeln
FrAtraverse Medical co-founder, CEO John Slump launches Metis MedTech as J&J closes deal1
FrJ&J granted Tremfya label expansion for joint damage in psoriatic arthritis2
FrJohnson & Johnson: FDA Approves Label Expansion For TREMFYA230NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced the FDA has approved a supplemental Biologics License Application to include evidence in the TREMFYA label for the inhibition of progression...
► Artikel lesen
FrJohnson & Johnson: FDA approves label expansion, cementing TREMFYA as the only IL-23 inhibitor proven to help stop further joint damage107TREMFYA® showed significant inhibition of structural joint damage in adults with active psoriatic arthritis HORSHAM, Pa., May 28, 2026 /PRNewswire/ -- Johnson &...
► Artikel lesen
DoLaser Photonics Corp.: Laser Photonics Expands into Precision Medical Device Manufacturing with Custom Laser Drilling System Order from Johnson & Johnson369$250K Development System Order from Johnson & Johnson Represents Entry into Medical Device Manufacturing; Successful Validation Could Enable Broader Deployment Across Manufacturing Lines ORLANDO, FL...
► Artikel lesen
DoJ&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?3
DoIs Johnson & Johnson Stock Outperforming the Dow?4
MiJ&J's Abiomed issues another alert for Impella after certain devices fail to meet design specs3
MiAs J&J separates from its orthopedics business, it's laying off 56 employees in New Jersey5
MiJohnson & Johnson CMO explains advances behind 'game-changer' Shockwave C2 Aero catheter3
DiDividendenbekanntmachungen (26.05.2026)10.712 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  AAC TECHNOLOGIES HOLDINGS INC  KYG2953R1149  0,35 HKD  0,0383 EUR  ADEIA INC  US00676P1075  0,05 USD  0,0429 EUR  ALTRI SGPS SA  PTALT0AE0002 - 0...
► Artikel lesen
DiJ&J's DePuy gains rights to MinMaxMedical Gemtrack tech7
DiJ&J's DePuy Synthes to acquire mini RF tracking tech for joint reconstruction, licenses bone graft sub6
MoWhy Johnson & Johnson Might Be the Smartest Dividend King to Buy in Today's Market23
Weiter >>
705 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
4,2,21